Astrazeneca plc ADR (NASDAQ:AZN) saw a downside of -1.04% to close Tuesday at $68.22 after subtracting -$0.72 on the day. The 5-day average trading volume is 4,870,940 shares of the company’s common stock. It has gained $69.25 in the past week and touched a new high 3 times within the past 5 days. An average of 4,267,400 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,783,566.
AZN’s 1-month performance is -0.04% or -$0.03 on its low of $65.71 reached on 09/11/23. The company’s shares have touched a 52-week low of $52.65 and high of $76.56, with the stock’s rally to the 52-week high happening on 04/25/23. YTD, AZN has achieved 0.62% or $0.42 and has reached a new high 12 times. However, the current price is down -10.89% from the 52-week high price.
Valuation Metrics
AZN stock has a beta of 0.50. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.75 while the price-to-book (PB) in the most recent quarter is 5.66, with the price to cash flow ratio at 22.92.
Astrazeneca plc ADR’s quick ratio for the period ended June 29 was 0.67, with the current ratio over the same period at 0.87. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.67, while the total debt to equity was 0.80.. In terms of profitability, the gross margin trailing 12 months is 68.78%. The trailing 12-month EBITDA margin is 23.26% while for the period ending June 29, Astrazeneca plc ADR’s operating margin was 14.93%. The firm’s gross profit as reported stood at $31.96 billion against revenue of $44.35 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 96.59% to $3.29 billion, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected AZN to announce $0.95 per share in earnings in its latest quarter, but it posted $1.08, representing a 13.70% surprise. EBITDA for the quarter stood at more than $3.73 billion. AZN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 59.13 billion, with total debt at $30.79 billion.
Let’s look briefly at Astrazeneca plc ADR (AZN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 52.71% to suggest the stock is trending Neutral, with historical volatility in this time period at 23.77%.
The stock’s 5-day moving average is $67.99, reflecting a +2.32% or $1.55 change from its current price. AZN is currently trading -0.61% above its 20-day SMA, -8.54% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +1.74% and SMA200 by-0.92%.
Stochastic %K and %D was 76.24% and 67.04% and the average true range (ATR) pointed at 1.25. The RSI (14) points at 50.73%, while the 14-day stochastic is at 70.96% with the period’s ATR at 1.21. The stock’s 9-day MACD Oscillator is pointing at 0.63 and 0.76 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Astrazeneca plc ADR (NASDAQ: AZN), Jefferies upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for AZN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate AZN as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 25 have offered a “buy” rating.
What is AZN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $63.00 and a high of $106.75, with their median price target at $82.57. Looking at these predictions, the average price target given by analysts is for Astrazeneca plc ADR (AZN) stock is $83.81.
